Kantarjian HM - Search Results

1

Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.

Roboz GJ, Giles FJ, Ritchie EK, Allen-Bard S, Curcio TJ, Wilkes MA, Park SL, Kantarjian HM, Faderl S, Ravandi F, Kelner MJ, Feldman EJ. Roboz GJ, et al. Among authors: kantarjian hm. J Clin Oncol. 2007 Jan 1;25(1):10-5. doi: 10.1200/JCO.2006.06.6209. Epub 2006 Dec 4. J Clin Oncol. 2007. PMID: 17146106 Clinical Trial.

2

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.

Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Grunewald R, et al. J Clin Oncol. 1992 Mar;10(3):406-13. doi: 10.1200/JCO.1992.10.3.406. J Clin Oncol. 1992. PMID: 1740680 Clinical Trial.

3

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ. Keating MJ, et al. J Clin Oncol. 1989 Aug;7(8):1071-80. doi: 10.1200/JCO.1989.7.8.1071. J Clin Oncol. 1989. PMID: 2666590

4

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, et al. Estey E, et al. J Clin Oncol. 1994 Apr;12(4):671-8. doi: 10.1200/JCO.1994.12.4.671. J Clin Oncol. 1994. PMID: 7512125 Clinical Trial.

5

Quesnel B, Kantarjian H, Bjergaard JP, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, et al. Quesnel B, et al. J Clin Oncol. 1993 Dec;11(12):2370-9. doi: 10.1200/JCO.1993.11.12.2370. J Clin Oncol. 1993. PMID: 8246025 Review.

6

Acute myeloid leukemia-type chemotherapy for myelodysplasia.

Anderlini P, Pierce S, Kantarjian H, Estey E. Anderlini P, et al. J Clin Oncol. 1996 Apr;14(4):1404-5. doi: 10.1200/JCO.1996.14.4.1404. J Clin Oncol. 1996. PMID: 8648402 No abstract available.

7

Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine.

Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Estey E, et al. J Clin Oncol. 1997 Feb;15(2):483-90. doi: 10.1200/JCO.1997.15.2.483. J Clin Oncol. 1997. PMID: 9053469 Clinical Trial.

8

Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.

Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M. Kornblau SM, et al. J Clin Oncol. 1997 May;15(5):1796-802. doi: 10.1200/JCO.1997.15.5.1796. J Clin Oncol. 1997. PMID: 9164187 Clinical Trial.

9

Biology and treatment of chronic myelogenous leukemia.

Giles FJ, Kantarjian HM. Giles FJ, et al. Among authors: kantarjian hm. Oncology (Williston Park). 1997 Sep;11(9):1295-300; discussion 1302-10. Oncology (Williston Park). 1997. PMID: 9306419

10

Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.

Gandhi V, Plunkett W, Kantarjian H, Talpaz M, Robertson LE, O'Brien S. Gandhi V, et al. J Clin Oncol. 1998 Jul;16(7):2321-31. doi: 10.1200/JCO.1998.16.7.2321. J Clin Oncol. 1998. PMID: 9667246 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,618 results

Search Page